Verty Aaron N A, Singh Malini E, McGregor Iain S, Mallet Paul E
School of Psychology, University of New England, Armidale, 2351 NSW, Australia.
Psychopharmacology (Berl). 2003 Jul;168(3):314-23. doi: 10.1007/s00213-003-1451-9. Epub 2003 Apr 17.
Considerable interplay exists between the brain's opioid and cannabinoid systems. These systems are both involved in the control of appetite and research supports the notion that the opioid system modulates the role of the cannabinoid system on appetite. However, the ability of the cannabinoid system to modulate the opioid system's control over appetite has not been well studied.
The present study examined the role of cannabinoid CB(1) receptors in the control of opioid-induced feeding, and sought to identify specific brain regions underlying this role.
After being habituated to the test environment and injection procedure, sated rats were injected with the cannabinoid CB(1) receptor antagonist SR 141716 (0.03-3.0 mg/kg, IP). Thirty minutes later, morphine or its vehicle were administered systemically (2.5 mg/kg SC, experiments 1 and 2) or intracranially into the nucleus accumbens (nAcc, experiment 3) or paraventricular nucleus of the hypothalamus (PVN, experiment 4). Food intake and locomotor activity was then recorded for 120 min.
A significant increase in food intake was observed following systemic and intracranial (10 nmol) application of morphine in all experiments. SR 141716 suppressed systemic and intra-PVN morphine induced feeding (experiments 2 and 4), but did not attenuate food intake induced by intra-nAcc application of morphine (experiment 3).
Because SR 141716 had no effect on intra-nAcc morphine-stimulated feeding, it would appear that cannabinoid receptors do not modify opioid-mediated hedonic responses to food. Rather, we conclude that cannabinoid CB(1) receptor blockade may suppress opioid-induced feeding by stimulating the release of satiety-related peptides within the hypothalamus. Further, because SR 141716 did not block morphine induced locomotor activity, the observed effects on feeding do not appear to be due to a non-specific reduction in motivated behaviour.
大脑的阿片类和大麻素系统之间存在着相当大的相互作用。这些系统都参与了食欲的控制,并且研究支持阿片类系统调节大麻素系统对食欲的作用这一观点。然而,大麻素系统调节阿片类系统对食欲控制的能力尚未得到充分研究。
本研究考察了大麻素CB(1)受体在阿片类诱导进食控制中的作用,并试图确定这一作用背后的特定脑区。
在适应测试环境和注射程序后,给饱腹的大鼠注射大麻素CB(1)受体拮抗剂SR 141716(0.03 - 3.0毫克/千克,腹腔注射)。30分钟后,全身注射吗啡或其溶媒(2.5毫克/千克,皮下注射,实验1和2),或颅内注射到伏隔核(实验3)或下丘脑室旁核(实验4)。然后记录120分钟内的食物摄入量和运动活动。
在所有实验中,全身和颅内(10纳摩尔)应用吗啡后均观察到食物摄入量显著增加。SR 141716抑制了全身和下丘脑室旁核内吗啡诱导的进食(实验2和4),但并未减弱伏隔核内注射吗啡诱导的食物摄入量(实验3)。
由于SR 141716对伏隔核内吗啡刺激的进食没有影响,因此大麻素受体似乎不会改变阿片类对食物的享乐反应。相反,我们得出结论,大麻素CB(1)受体阻断可能通过刺激下丘脑内饱腹感相关肽的释放来抑制阿片类诱导的进食。此外,由于SR 141716并未阻断吗啡诱导的运动活动,因此观察到的对进食的影响似乎并非由于动机行为的非特异性降低。